Invasive group A streptococcal disease and intensive care unit admissions

2002 ◽  
Vol 28 (12) ◽  
pp. 1822-1824 ◽  
Author(s):  
Zuber Mulla
2010 ◽  
Vol 60 (2) ◽  
pp. 183-186 ◽  
Author(s):  
Alison Timmis ◽  
Kate Parkins ◽  
Ildiko Kustos ◽  
F. Andrew I. Riordan ◽  
Androulla Efstratiou ◽  
...  

2000 ◽  
Vol 181 (2) ◽  
pp. 631-638 ◽  
Author(s):  
Ellen M. Mascini ◽  
Margriet Jansze ◽  
Joop F. P. Schellekens ◽  
James M. Musser ◽  
Joop A. J. Faber ◽  
...  

2015 ◽  
Vol 144 (5) ◽  
pp. 1018-1027 ◽  
Author(s):  
R. BOYD ◽  
M. PATEL ◽  
B. J. CURRIE ◽  
D. C. HOLT ◽  
T. HARRIS ◽  
...  

SUMMARYAlthough the incidence of invasive group A streptococcal disease in northern Australia is very high, little is known of the regional epidemiology and molecular characteristics. We conducted a case series of Northern Territory residents reported between 2011 and 2013 withStreptococcus pyogenesisolates from a normally sterile site. Of the 128 reported episodes, the incidence was disproportionately high in the Indigenous population at 69·7/100 000 compared to 8·8/100 000 in the non-Indigenous population. Novel to the Northern Territory is the extremely high incidence in haemodialysis patients of 2205·9/100 000 population; and for whom targeted infection control measures could prevent transmission. The incidences in the tropical north and semi-arid Central Australian regions were similar. Case fatality was 8% (10/128) and streptococcal toxic shock syndrome occurred in 14 (11%) episodes. Molecular typing of 82 isolates identified 28emmtypes, of which 63 (77%) were represented by fouremmclusters. Typing confirmed transmission between infant twins. While the diverse range ofemmtypes presents a challenge for effective coverage by vaccine formulations, the limited number ofemmclusters raises optimism should cluster-specific cross-protection prove efficacious. Further studies are required to determine effectiveness of chemoprophylaxis for contacts and to inform public health response.


2011 ◽  
Vol 17 (3) ◽  
pp. 358-364 ◽  
Author(s):  
B.R. Kittang ◽  
T. Bruun ◽  
N. Langeland ◽  
H. Mylvaganam ◽  
M. Glambek ◽  
...  

2000 ◽  
Vol 68 (11) ◽  
pp. 6384-6390 ◽  
Author(s):  
Brandi Limbago ◽  
Vikram Penumalli ◽  
Brian Weinrick ◽  
June R. Scott

Nutrients ◽  
2019 ◽  
Vol 11 (12) ◽  
pp. 2976 ◽  
Author(s):  
Won-Young Kim ◽  
Jae-Woo Jung ◽  
Jae Chol Choi ◽  
Jong Wook Shin ◽  
Jae Yeol Kim

This study aimed to identify septic phenotypes in patients receiving vitamin C, hydrocortisone, and thiamine using temperature and white blood cell count. Data were obtained from septic shock patients who were also treated using a vitamin C protocol in a medical intensive care unit. Patients were divided into groups according to the temperature measurements as well as white blood cell counts within 24 h before starting the vitamin C protocol. In the study, 127 patients included who met the inclusion criteria. In the cohort, four groups were identified: “Temperature ≥37.1 °C, white blood cell count ≥15.0 1000/mm3” (group A; n = 27), “≥37.1 °C, <15.0 1000/mm3” (group B; n = 30), “<37.1 °C, ≥15.0 1000/mm3” (group C; n = 35) and “<37.1 °C, <15.0 1000/mm3” (group D; n = 35). The intensive care unit mortality rates were 15% for group A, 33% for group B, 34% for group C, and 49% for group D (p = 0.051). The temporal improvement in organ dysfunction and vasopressor dose seemed more apparent in group A patients. Our results suggest that different subphenotypes exist among sepsis patients treated using a vitamin C protocol, and clinical outcomes might be better for patients with the hyperinflammatory subphenotype.


2019 ◽  
Vol 21 (1) ◽  
pp. 63-70
Author(s):  
Tom Parks ◽  
Katherine Elliott ◽  
Theresa Lamagni ◽  
Kathryn Auckland ◽  
Alexander J. Mentzer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document